Abstract: Objective To investigate the safety of anlotinib + camrelizumab combined with radiotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) and its effect on serum tumor markers. Methods Ninety-six patients with advanced NSCLC who were diagnosed and treated at Chongming Hospital Affiliated to Shanghai University of Medicine & Health Sciences from July 2020 to July 2021 were selected as study subjects. They were divided into group A (receiving anlotinib + camrelizumab combined with radiotherapy, n=32), group B (receiving camrelizumab combined with radiotherapy, n=32) and group C (receiving radiotherapy, n=32) according to random number table method. After 4 cycles of treatment, disease control rate (DCR), objective response rate (ORR), carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), cytokeratin 19 fragment (CYFRA21-1), and toxicity were compared among three groups, and survival were compared until follow up to August 2023. Results The ORR and DCR of group A were higher than those of group B and group C (P＜0.05). After treatment, CEA, CA125 and CYFRA21-1 in group A were lower than those in group B and group C (P＜0.05). There was no significant difference in the incidence of toxic and side effects among the three groups (χ²=0.667, P=0.716). The 2-year survival rate (81.25%) in group A was higher than that in group B (56.25%) and group C (50.00%), and the survival time ［(21.75±5.08) months］ was longer than that in group B ［(18.47±7.00) months］ and group C ［(17.13±8.13) months］ (P＜0.05). Conclusion Anlotinib + camrellizumab combined with radiotherapy has a relatively ideal effect, which can not only reduce the expression levels of serum tumor markers, but also prolong the survival time of patients.